Cargando…

The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects

Mostrar otras versiones (1)

INTRODUCTION: Dolutegravir (DTG) is an HIV integrase strand transfer inhibitor approved for use in combination with other antiretrovirals for the treatment of HIV-infection in adults and adolescents. Metformin is a drug frequently used in diabetic HIV-infected patients, which requires titration to o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zong, Jian, Borland, Julie, Jerva, Fred, Wynne, Brian, Choukour, Mike, Song, Ivy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Poster Sessions – Abstract P052
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224846/ https://www.ncbi.nlm.nih.gov/pubmed/25394090 http://dx.doi.org/10.7448/IAS.17.4.19584

Ejemplares similares

The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects
por: Song, Ivy H., et al.
Publicado: (2016)

Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation
por: Song, Ivy, et al.
Publicado: (2016)

Plasma de convalescents du COVID-19 : premiers résultats en AURA
por: François, Marion, et al.
Publicado: (2021)

No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects
por: Ross, Lisa L., et al.
Publicado: (2016)

Pharmacokinetics of Dolutegravir When Administered With Mineral Supplements in Healthy Adult Subjects
por: Song, Ivy, et al.
Publicado: (2015)

Transient endothelial injury and release of lupus anticoagulant in COVID-19
por: Trimaille, A., et al.
Publicado: (2022)

ALTERAÇÕES RADIOLÓGICAS SEQUELARES ATÍPICAS DA COVID‐19: RELATO DE CASO
por: Lima, Marina Deorce de, et al.
Publicado: (2021)

Impact de l’hyperthyroïdie sur le pronostic des malades ayant une infection sévère au Covid-19
por: Nouira, H., et al.
Publicado: (2021)

CONHECIMENTO DA POPULAÇÃO BRASILEIRA SOBRE COVID-19 E FATORES ASSOCIADOS NOS PRIMEIROS MESES DA PANDEMIA
por: Rosa, Davi Amaral Cesário, et al.
Publicado: (2022)

PERFIL CLÍNICO EPIDEMIOLÓGICO E DESFECHOS DA PRIMEIRA ONDA DE COVID-19 EM ANÁPOLIS, GOIÁS
por: Carvajal, Deborah Lopes Mota, et al.
Publicado: (2022)

Poids, composition corporelle et risque d’infection par le SARS-CoV-2 au sein d’une large population
por: Deschasaux-Tanguy, M., et al.
Publicado: (2022)

Impact de la Covid-19, du confinement et de l’isolement social sur l’état nutritionnel : projet e-Nutriv
por: Ghanem, J., et al.
Publicado: (2022)

ADESÃO À LIMPEZA CONCORRENTE DE SUPERFÍCIES DE ALTO TOQUE EM UMA UNIDADE DE TERAPIA INTENSIVA EXCLUSIVA PARA ATENDIMENTO DE PACIENTES COM COVID-19
por: Fram, Dayana Souza, et al.
Publicado: (2022)

Maladie de Kikuchi-Fujimoto post-vaccin COVID-19 : à propos de 1 cas
por: Mekki, S., et al.
Publicado: (2022)

Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir
por: Johnson, Mark, et al.
Publicado: (2014)

Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment
por: Weller, Stephen, et al.
Publicado: (2013)

New dolutegravir resistance pattern identified in a patient failing antiretroviral therapy
por: Carganico, Andreas, et al.
Publicado: (2014)

An indirect comparison of efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir and dolutegravir + abacavir/lamivudine
por: Rogatto, Felipe, et al.
Publicado: (2014)

Use of dolutegravir in two INI-experienced patients with multiclass resistance resulted in excellent virological and immunological responses
por: Marije Hofstra, Laura, et al.
Publicado: (2014)

Pharmacokinetics of Single-Dose Dolutegravir in HIV-Seronegative Subjects With Moderate Hepatic Impairment Compared to Healthy Matched Controls
por: Song, Ivy H, et al.
Publicado: (2013)

Relative Bioavailability of a Dolutegravir Dispersible Tablet and the Effects of Low‐ and High‐Mineral‐Content Water on the Tablet in Healthy Adults
por: Buchanan, Ann M., et al.
Publicado: (2017)

Dolutegravir Has No Effect on the Pharmacokinetics of Oral Contraceptives With Norgestimate and Ethinyl Estradiol
por: Song, Ivy H., et al.
Publicado: (2015)

A clinical and pharmacokinetic study of the combination of etravirine plus raltegravir in HIV patients with expanded intolerance or resistance
por: Bañón, Sara, et al.
Publicado: (2014)

The efficacy, pharmacokinetics, safety and cardiovascular risks of switching nevirapine to rilpivirine in HIV-1 patients: the RPV switch study
por: Rokx, Casper, et al.
Publicado: (2014)

Predictors of lack of serological response to syphilis treatment in HIV-infected subjects
por: Spagnuolo, Vincenzo, et al.
Publicado: (2014)

Overall and cause-specific mortality in HIV-positive subjects compared to the general population
por: Alejos, Belen, et al.
Publicado: (2014)

Long-term efficacy and safety of E/C/F/TDF vs EFV/FTC/TDF and ATV+RTV+FTC/TDF in HIV-1-infected treatment-naïve subjects ≥50 years
por: Gazzard, Brian, et al.
Publicado: (2014)

Effectiveness of a team intervention in reducing modifiable cardiovascular disease risk in HIV-infected subjects on antiretroviral therapy
por: Bloch, Mark, et al.
Publicado: (2014)

Renal safety profile of STB in virologically suppressed subjects from two randomized phase 3b switch trials
por: Reeves, Iain, et al.
Publicado: (2014)

Long term effectiveness of once-daily unboosted atazanavir plus abacavir/lamivudine as a switch strategy in subjects with virological suppression
por: Llibre, Josep M, et al.
Publicado: (2014)

Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study
por: Spagnuolo, Vincenzo, et al.
Publicado: (2014)

Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients
por: Zhang, Jianping, et al.
Publicado: (2015)

Reducing turnaround time for laboratory test results does not improve retention of stable HIV-infected adults on POV program: experience from Uganda
por: Maselle, Edna, et al.
Publicado: (2014)

1009. Dolutegravir and Doravirine in Combination: When Standard Antiretroviral Regimens are Unacceptable
por: Denyer, Rachel, et al.
Publicado: (2020)

Failure of daily tenofovir to prevent HIV transmission or the establishment of a significant viral reservoir despite continued antiretroviral therapy
por: Davies, Olubanke, et al.
Publicado: (2014)

Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir
por: Song, Ivy, et al.
Publicado: (2014)

The importance of viral blips and duration of therapy initiated in primary infection in maintaining viral control after stopping cART
por: Fidler, Sarah, et al.
Publicado: (2014)

Relationship between discordant response to HAART, Tregs, immune activation and low-level viraemia
por: Saison, Julien, et al.
Publicado: (2014)

Patient preferences for characteristics of antiretroviral therapies: results from five European countries
por: Gazzard, Brian, et al.
Publicado: (2014)

Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects
por: Hausner, Helene, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vgba38ea623ser453qnpu7guro